Compare PNW & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNW | DVA |
|---|---|---|
| Founded | 1985 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Misc Health and Biotechnology Services |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | 10.0B |
| IPO Year | 1994 | 2002 |
| Metric | PNW | DVA |
|---|---|---|
| Price | $103.13 | $149.37 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 14 | 4 |
| Target Price | $98.77 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 917.2K | 613.1K |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.50% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 5.05 | ★ 9.84 |
| Revenue | $5,339,939,000.00 | ★ $13,643,069,000.00 |
| Revenue This Year | $5.43 | $3.85 |
| Revenue Next Year | $6.82 | $3.07 |
| P/E Ratio | $20.60 | ★ $15.00 |
| Revenue Growth | 4.20 | ★ 6.46 |
| 52 Week Low | $85.32 | $101.00 |
| 52 Week High | $104.92 | $159.42 |
| Indicator | PNW | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 56.43 | 50.55 |
| Support Level | $86.28 | $145.62 |
| Resistance Level | $104.03 | $152.31 |
| Average True Range (ATR) | 1.63 | 3.79 |
| MACD | 0.04 | -0.59 |
| Stochastic Oscillator | 68.23 | 53.65 |
Pinnacle West is a holding company whose principal subsidiary is Arizona Public Service, a vertically integrated electric utility serving approximately 1.4 million customers across a 35,000-square-mile territory in central Arizona, including the Phoenix area. APS owns or leases 6.5 gigawatts of power generation capacity, including a 29% ownership stake in one of the largest nuclear plants in the US, Palo Verde. Half of the electricity that APS supplies to customers comes from clean energy sources, including nuclear.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.